Weighing Over Diet Pills – A Conclusion

Among the four diet pills mentioned, there seems to be a dearth of information regarding the efficacy of these products when used by people of each age group or with other conditions. Among the four, only Stacker 2 has an outside source that claimed it was effective against another product in the market. However, this study is still not so substantial to claim that Stacker 2 is the best among the three other products researched. Most of the products have been freed of the harmful ephedra and are now relying on herbal extracts to promote weight loss. Sadly, two of the products researched (Trimspa and Zantrex 3) have had bad publicities that were found out regarding the ill effects of using these products. Thus, it is still recommended that further academic and scientific studies are needed to be done to prove the efficacy and the safety of these diet pills.

According to Hirsch (1999), none of today’s drugs treats the root cause of obesity, which is a body with a set point that is too high. Instead, the drugs attempt to keep the body artificially below that set point by affecting appetite, metabolism, or the absorption of food in the intestines. The body maintains its set point through a variety of interrelated systems, and when a drug affects one of these systems—appetite, say—the body will compensate in another area, for instance, by slowing down the metabolism. To get around this, the drug treatment must push exceptionally hard on one system or moderately hard on several systems, and either of these approaches makes it likely that the drugs will have unwanted side effects. Using drugs to modify the behavior of systems that are functioning perfectly is asking for trouble. This is why we should not take these diet pills without any prescription or recommendation from our physician to avoid these pills’ deleterious effects on our health and well-being.

Works Cited

Carey, John. “How Safe Are Diet Supplements? FDA Regulation is Weak, So Private Watchdogs are Stepping In.” Business Week, 3969 (Jan 30, 2006).

Connolly, H.M., Crary, J.L., McGoon M.D., et al. “Valvular Heart Disease Associated with Fenfluramine-Phentermine”, New England Journal of Medicine, 337(1997): 581-588.

Evans, John T., and Robert L. Kerner Jr. “A Primer on Fen-Phen Litigation: Allegations and Defenses.” Defense Counsel Journal 65.3 (July 1998): 353.

Fiske, John. “Popular Culture.” Critical Terms for Literary Study. Ed. Frank Lentricchia and Thomas McLaughlin. 2nd ed. Chicago: University of Chicago Press, 1995. 321 – 335.

Frucht, Suzanne S., Christie Cox, David Johnson, Megan Moore, Debra Mosher, Megan Peterson, and Angela Posten. “The Effect of Dietary Weight Loss Supplements Containing Caffeine on the Mass and Metabolic Rate of Rats”, Transactions of the Missouri Academy of Science 39 (Annual 2005): 26-35.

Hirsch, Jules. “Obesity: Definition of the Problem,” in George A. Bray and Donna H. Ryan, eds., Nutrition, Genetics, and Obesity, Baton Rouge: Louisiana State University Press, 1999, 1-13.

Leptopril Website. FAQ. 27 September 2007.

Ling, Amy M. “FDA to Ban Sales of Dietary Supplements Containing Ephedra.” Journal of Law, Medicine & Ethics 32.1 (2004): 184.

Mowrey, Daniel B. “Beyond Ephedra: Presenting a New and Superior Product for Energy and Effective Weight Loss: Zantrex®-3”. 27 September 2007.

Pool, Robert. Fat: Fighting the Obesity Epidemic. New York: Oxford University Press, 2001.

Saul, Stephanie.  “FDA Questions a Planned Over-the-Counter Diet Drug”, New York Times (January 21, 2006). 27 September 2007.

Swain, Liz. “Diet Pills.” Drugs and Controlled Substances: Information for Students. Ed. Stacey L. Blachford and Kristine Krapp. Detroit: Gale, 2003.

Trimspa Website. Testimonials. 27 September 2007.